4 November 2009 – Aerocrine AB (OMX Nordic Exchange: AERO) announced that Aerocrine and Panasonic Shikoku Electronics, CO., LTD (PSEC) have entered into a long-term agreement to develop, manufacture and market new generation products for airway inflammation monitoring using exhaled nitric oxide.
PSEC, a wholly owned subsidiary of Panasonic Corporation, is a world class electronic development, manufacturing and marketing corporation with extensive experience in designing and manufacturing consumer and professional medical devices. Aerocrine is a clinically based medical technology corporation that discovered exhaled nitric oxide monitoring for clinical use in asthma care and leads the market with proprietary technology and products for airway inflammation measurement.
Under the agreement, Aerocrine and PSEC will collaborate to develop future generations of products for airway inflammation monitoring for both clinical and personal use. PSEC will be responsible for the worldwide manufacture and supply of the products and Aerocrine will be responsible for regulatory approvals, method development and global commercialization... Aerocrine's Press Release -
Blog Archive
-
▼
2009
(26)
-
▼
November
(10)
- ZaBeCor Pharmaceuticals : Phase II Clinical Trial ...
- SuperGen : MP-470 Demonstrates Clinical Benefit in...
- Entest BioMedical : Treatment of Chronic Obstructi...
- NovaRx : FDA Approval of Protocol Amendment to Sp...
- Sagent Pharmaceuticals launches VINORELBINE INJECT...
- Almac and Lilly Partner on Companion Diagnostic De...
- Aerocrine and Panasonic Shikoku Electronics : ast...
- Pulmatrix : Company Developing Novel Therapies to ...
- Ingen Technologies Brings Aboard Leading OEM Partn...
- Sequenom : Launch of SensiGene Cystic Fibrosis Car...
-
▼
November
(10)
Nov 16, 2009
Aerocrine and Panasonic Shikoku Electronics : asthma partnership
Libellés :
Aerocrine,
Asthma,
Panasonic Shikoku Electronics (PSEC)